leisure time -WSS

leisure time

author：entertainment 2025-09-27 09:45:58 - browse：4

Stock illustration of computer and medication — Adobe

Half a year after selling its assets at bankruptcy auction, Pear Therapeutics’ most significant digital treatments will find a new life as part of PursueCare, which provides online addiction care and mental health counseling.

PursueCare today announced it had raised a $20 million Series B round and that it had acquired Pear’s portfolio of apps that treat people with addiction problems. PursueCare’s CEO Nick Mercadante told STAT the company hopes to develop the market for the treatments where Pear could not, by taking advantage of its access to patients and insurers.

“My view of digital therapeutics is that those point solutions really need a horse to draw the carriage,” he said. “You need a willing and capable service provider that says we’re going to make this a big part of real world care and… then show the health plans how it can save them money in the real world without extra thinking.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： First Opinion Podcast: How to protect health care in times of war

hotspot

WSS

Physician subsidies by hospitals soar in wake of No Surprises Act

eGenesis tests gene

My yearlong odyssey to get my son’s ADHD medication covered

Meta's Zuckerberg and Chan on track to put $50 billion into science

NIH director takes cautious approach to Biden drug pricing priority

Francis Collins on trust in science and how Covid communications failed

focus

leisure time

Wikipedia

Medical records are filled with copy

Physician subsidies by hospitals soar in wake of No Surprises Act

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Think you might have Covid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

eGenesis tests gene

Apple is now the first public company to be valued at $3 trillion

Prior authorization will have to move faster under new Biden rule

Moonlake's readout produced a cash windfall. Risks remain

FDA has safety concerns on CRISPR

hotspot

FDA clears AI tool for detecting skin cancer

Test for long Covid? Researchers find new clue in blood samples

Medtronic CEO on promising devices for diabetes, hypertension

Meta's Zuckerberg and Chan on track to put $50 billion into science

NIH director takes cautious approach to Biden drug pricing priority

Biden's order seeks to regulate AI risk without stifling innovation

explore

hotspot

hotspot

explore